RxDoctor Payments DataLook up a doctor →

Adam Meade

Nurse Practitioner · Beckley, WVNPI 1023440005

Payments from drug & device makers

$10,362in general payments, 2019–2025

Across 624 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$3K
  • E.r. Squibb & Sons, L.L.C.$695
  • Sun Pharmaceutical Industries Inc.$655
  • Lilly USA, LLC$336
  • Dermavant Sciences, Inc.$291
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$9,61993%
  • Education$7427%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,362 in reported general payments places this provider in the 95th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$236,244
Medicare patients
1,022
Services billed
4,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa18$380,034
TremfyaGuselkumab18$247,872
Dupixent PenDupilumab64$242,997
Humira(Cf) PenAdalimumab22$206,343
Clobetasol Propionate261$10,977
Ketoconazole241$5,036
Metronidazole67$4,380
Fluorouracil47$2,868
Ammonium Lactate99$2,539
Triamcinolone Acetonide210$2,217
Imiquimod73$1,820
Doxycycline Hyclate120$1,548
Clindamycin Phosphate38$1,447
Tretinoin12$1,030
Mupirocin87$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,655$247,87218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →